At Nexus BioQuest, we deliver high-standard studies designed to support regulatory submissions like INDs and similar filings. We know that success in these complex studies depends on precise planning and structured documentation. That’s why our scientific teams develop detailed scientific study plans—each one a roadmap with clear milestones that keep our team and clients aligned from start to finish.
At Nexus BioQuest, quality is at the heart of everything we do. That’s why we rely on an electronic notebook system to ensure accurate, real-time record-keeping for our IND-supporting studies. This system captures every step of our experimental workflow, creating a complete and traceable record that reflects our commitment to data integrity. The team’s dedication to quality is maintained throughout the study; finishing with high-standard reports that present data clearly and accurately, ready to support a range of regulatory submissions.
While we don’t operate under GLP, our internal quality standards are upheld by an RQA-certified QA team, with audits performed at key milestones. By taking a proactive approach we ensure our data is reliable, compliant, and ready to meet regulatory standards. When you work with us, you’re partnering with a team committed to delivering research that’s dependable, trustworthy, and built to drive progress.
Written by Danielle Clark
Integrity is one of our four core values at Nexus BioQuest. It drives our commitment to delivering accurate and fully traceable data that our clients can trust. Every process we follow—from study design to data reporting—adheres to ethical and scientific standards to ensure that our results are robust and reproducible. For us, integrity isn’t just about what we deliver; it’s about how we do it.
Integrity also extends to our relationships. We believe in open, consistent communication and see ourselves as true partners in every study. From study kick-off to final reports, we keep our clients informed at every stage, making sure they feel confident in both the process and the outcomes and allows us to build strong, lasting partnerships. This collaborative approach enables our clients to have confidence in the study process, knowing they are supported by a team of scientists striving to producing quality results.
Beyond client relationships, integrity also means continuous improvement to the service we provide. Our teams regularly review our methods and processes, pushing ourselves to uphold the high scientific standards our clients expect. By holding ourselves accountable, we provide research that our clients can rely on time after time.
The British Society for Immunology (BSI) ran their first Immune Therapies Summit at the end of November, which Courteney Arthur and Dr Rhiannon Jenkinson attended. It was a great couple of days and fantastic to discuss science and catch up with people we knew, as well as network and make new connections.
There were some excellent talks across different therapeutic areas, including immune-oncology, autoimmunity, inflammation and neuro-inflammation and the cross-disciplinary conference approach led to interesting discussions and questions. In addition, the breakout focus sessions led to some stimulating discussions within small groups. I attended the targeting innate immunity and beyond checkpoint inhibitors focus sessions, and the discussion was wide-ranging. Having the chance to discuss different perspectives from different viewpoints was a real plus, from the challenges faced from early drug discovery through to clinical trials and then through to the clinician’s perspective of the real-life experience of treating patients with approved therapies.
In terms of the therapeutic modalities and biomarker strategies utilised, these were wide-ranging; the use of vaccines was discussed across oncology, neurodegeneration, and infectious disease. The use of cellular therapy strategies to deplete B cells in patients suffering severe auto-immune disease was inspiring in terms of the positive clinical outcomes for many of the patients for a review, see DOI https://doi.org/10.1038/s41584-024-01139-z. Hearing a fantastic synopsis of the IL-23 pathway from its discovery through to its targeting for treating inflammatory diseases was a great example of the translation of blue skies research into clinical treatments. The keynote presentation on viral immunotherapy highlighted several innovative strategies with oncolytic and non-oncolytic viruses for mobilising an anti-tumour response in solid tumours resistant to ICI and how this approach can also target distal metastases.
Finally, three really interesting talks one on how targeting the right therapy to the right patients is key for efficacy; if targeting a specific pathway fails in the clinic but has been positive all the way through discovery and the appropriate biomarkers upregulated in the clinic, how this could be a combination of the right pathway but wrong molecule, potentially the wrong subset of patients or the wrong stage of disease. The second on repurposing of drugs between autoimmune and oncology indications. The third on how understanding biomarkers and the use of biomarkers can help us transition away from ‘imprecision’ medicine in the treatment of arthritis and IBD.
From a CRO perspective, hearing the scientific advances in developing new therapeutics and the challenges people are facing and the research solutions they utilise is inspiring and gets the scientific juices flowing in terms of assays we can develop to support our client’s drug discovery programs.
The BSI should be commended on their approach at enabling discussion, and I’m excited to see how they develop this approach in future conferences.
Anna Willox, PhD
Head of European Business Development
As part of Nexus BioQuest’s ongoing commitment to staying at the forefront of immunology and drug discovery, I had the opportunity to attend the SLAS (Society for Laboratory Automation and Screening) meeting in London this December. This event served as an invaluable platform for networking with industry leaders, learning about the latest advancements in laboratory automation, and exploring new technologies that could enhance our offerings at Nexus BioQuest.
Attending SLAS allowed me to connect with potential partners, discover cutting-edge developments in screening technologies, and exchange insights on best practices in drug discovery. I look forward to leveraging the knowledge and relationships gained at the event to help Nexus BioQuest continue to provide top-tier services for our clients, particularly in areas like immune profiling, cell-based assays, and immunotherapy development.
It was a fantastic experience to engage with experts and peers in the field, and I’m excited to see how the connections and insights from SLAS will help Nexus BioQuest expand its capabilities and strengthen its position in the industry. It was a true pleasure meeting so many inspiring individuals, including Sonia Houghton, Del Trezise, Jeroen Verheyen, Scott Mitchell, Dahir Ahmed, Thomas Richardson, Rob Howes, and reconnecting with familiar faces like Tom Crabbe after many years!
A huge thank you to the organizers, SLAS (Vicki Loise) and ELRIG (Sanj Kumar), as well as the sponsors, for creating such a wonderful opportunity to network and hear exciting presentations on innovations in the bioscience and drug discovery sectors, including new modalities.
I’m already looking forward to next year’s events!